Fraction Lipophilicity Index (FLI). A drug-like metric for orally administered ionizable drugs

References

• P.D. Leeson and B. Springthorpe, The influence of drug-like concepts on decision-making in medicinal chemistry, Nat. Rev. Drug. Discov. 11 (2007), pp. 881–890. doi:10.1038/nrd2445.
   Google Scholar
• I. Yusof and M.D. Segall, Considering the impact drug-like properties have on the chance of success, Drug. Discover. Today 18 (2013), pp. 659–666. doi:10.1016/j.drudis.2013.02.008.
   PubMed Web of Science ®Google Scholar
• J.D. Hughes, J. Blagg, D.A. Price, S. Bailey, G.A. Decrescenzo, R.V. Devraj, E. Ellsworth, Y.M. Fobian, M.E. Gibbs, R.W. Gilles, N. Greene, E. Huang, T. Krieger-Burke, J. Loesel, T. Wager, L. Whiteley, and Y. Zhang, Physicochemical drug properties associated with in vivo toxicological outcomes, Bioorg. Med. Chem. Lett. 18 (2008), pp. 4872–4875. doi:10.1016/j.bmcl.2008.07.071.
   PubMed Web of Science ®Google Scholar
• M. Wenlock, R.P. Austin, P. Barton, A.M. Davis, and P.D. Leeson, A comparison of physiochemical property profiles of development and marketed oral drugs, J. Med. Chem. 46 (2003), pp. 1250–1256. doi:10.1021/jm021053p.
   PubMed Web of Science ®Google Scholar
• G.R. Bickerton, G.V. Paolini, J. Besnard, S. Muresan, and A.L. Hopkins, Quantifying the chemical beauty of drugs, Nat. Chem. 4 (2012), pp. 90–98. doi:10.1038/nchem.1243.
   PubMed Web of Science ®Google Scholar
• C. Hansch, J.P. Bjorkroth, and A. Leo, Hydrophobicity and central nervous system agents: On the principle of minimal hydrophobicity in drug design, J. Pharm. Sci. 76 (1987), pp. 66–687. doi:10.1002/jps.2600760902.
   Web of Science ®Google Scholar
• C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney, In vitro models for selection of development candidates. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug. Deliv. Rev. 23 (1997), pp. 3–25. doi:10.1016/S0169-409X(96)00423-1.
   Web of Science ®Google Scholar
• M. Congreve, R. Carr, C. Murray, and H. Jhoti, A “rule of three” for fragment-based lead discovery? Drug. Discov. Today. 8 (2003), pp. 876–877. doi:10.1016/S1359-6446(03)02831-9.
   PubMed Web of Science ®Google Scholar
• D.F. Veber, S.R. Johnson, H.-Y. Cheng, B.R. Smith, K.W. Ward, and K.D. Kopple, Molecular properties that influence the oral bioavailability of drug candidates, J. Med. Chem. 45 (2002), pp. 2615–2623. doi:10.1021/jm020017n.
   PubMed Web of Science ®Google Scholar
• T.I. Oprea, Current trends in lead discovery: Are we looking for the appropriate properties? J. Comput. Aided. Mol. Des. 16 (2002), pp. 325–334.
   PubMed Web of Science ®Google Scholar
• T.J. Ritchie and S.J.F. Macdonald, How drug-like are ‘ugly’ drugs: Do drug-likeness metrics predict ADME behaviour in humans? Drug. Discover. Today 19 (2014), pp. 489–495. doi:10.1016/j.drudis.2014.01.007.
   PubMed Web of Science ®Google Scholar
• M.M. Hann, Molecular obesity, potency and other addictions in drug discovery, Med. Chem. Comm. 2 (2011), pp. 349–355. doi:10.1039/c1md00017a.
   Web of Science ®Google Scholar
• A.L. Hopkins, C.R. Groom, and A. Alex, Ligand efficiency: A useful metric for lead selection, Drug. Discover. Today 9 (2004), pp. 430–431. doi:10.1016/S1359-6446(04)03069-7.
   PubMed Web of Science ®Google Scholar
• A.L. Hopkins, G.M. Keserü, P.D. Leeson, D.C. Rees, and C.M. Reynolds, The role of ligand efficiency metrics in drug discovery, Nat. Rev. Drug. Discover. 13 (2014), pp. 105–121. doi:10.1038/nrd4163.
   PubMed Web of Science ®Google Scholar
• G.M. Keserű and G.M. Makara, The influence of lead discovery strategies on the properties of drug candidates, Nat. Rev. Drug. Discov. 8 (2009), pp. 203–212. doi:10.1038/nrd2796.
   PubMed Web of Science ®Google Scholar
• Y.C. Martin, A bioavailability score, J. Med. Chem. 48 (2005), pp. 3164–3170. doi:10.1021/jm0492002.
   PubMed Web of Science ®Google Scholar
• G. Vistoli, A. Predretti, and B. Testa, Assessing drug-likeness–what are we missing? Drug. Discov. Today 13 (2008), pp. 285–294. doi:10.1016/j.drudis.2007.11.007.
   PubMed Web of Science ®Google Scholar
• J.E.A. Comer High-throughput Measurement of log D and pKa, in Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability, H. van de Waterbeemd, H. Lennernas, and P. Artursson, eds., WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, 2003, pp. 2.1, 23.
   Google Scholar
• M.J. Waring, Defining optimum lipophilicity and molecular weight ranges for drug candidates – Molecular weight dependent lower log D limits based on permeability, Biorg. Med. Chem. Lett. 19 (2009), pp. 2844–2851. doi:10.1016/j.bmcl.2009.03.109.
   PubMed Web of Science ®Google Scholar
• B. Testa, P.A. Carrupt, P. Gaillard, and R.-S. Tsai, Intramolecular interactions encoded in lipophilicity: Their nature and significance, in Lipophilicity in Drug Action and Toxicology, V. Pliska, B. Testa, and H. van de Waterbeemd, eds., VCH, Weinheim, 1995, pp. 49–71.
   Google Scholar
• A. Tsantili-Kakoulidou, M. Chatzopoulou, and V.J. Demopoulos, Fraction lipophilicity index (FLI): A metric for assessing oral drug-likeness of ionizable chemical entities, IJQSPR 4 (2019), pp. 41–66.
   Google Scholar
• M.D. Shultz, Two decades under the influence of the rule of five and the changing properties of approved oral drugs, J. Med. Chem. 62 (2019), pp. 1701–1714. doi:10.1021/acs.jmedchem.8b00686.
   PubMed Web of Science ®Google Scholar
• D. Newby, A. Freitas, and T. Ghafourian, Decision trees to characterise the roles of permeability and solubility on the prediction of oral absorption, Eur. J. Med. Chem. 90 (2015), pp. 751–765. doi:10.1016/j.ejmech.2014.12.006.
   PubMed Web of Science ®Google Scholar
• V.E. Thiel-Demby, J.E. Humphreys, L.A. St. John Williams, H.M. Ellens, N. Shah, A.D. Ayrton, and J.W. Polli, Biopharmaceutics classification system: Validation and learnings of an in vitro permeability assay, Mol. Pharmaceut. 6 (2009), pp. 11–18. doi:10.1021/mp800122b.
   PubMed Web of Science ®Google Scholar
• M.P. Gleeson, A. Hersey, D. Montanari, and J. Overington, Probing the links between in vitro potency, ADMET and physicochemical parameters, Nat. Rev. Drug. Discov. 3 (2011), pp. 197–208. doi:10.1038/nrd3367.
   Google Scholar
• H.A. Zhong, V. Mashinson, T.A. Woolman, and M. Zha, Understanding the molecular properties and metabolism of top prescribed drugs, Curr. Top. Med. Chem. 13 (2013), pp. 1290–1307.
   PubMed Web of Science ®Google Scholar